Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-8150
Authors: Dupont, Camille Amandine
Riegel, Kristina
Pompaiah, Malvika
Juhl, Hartmut
Rajalingam, Krishnaraj
Title: Druggable genome and precision medicine in cancer : current challenges
Online publication date: 16-Nov-2022
Year of first publication: 2021
Language: english
Abstract: The past decades have seen tremendous developments with respect to “specific” therapeutics that target key signaling molecules to conquer cancer. The key advancements with multiomics technologies, especially genomics, have allowed physicians and molecular oncologists to design “tailor-made” solutions to the specific oncogenes that are deregulated in individual patients, a strategy which has turned out to be successful though the patients quickly develop resistance. The swift integration of multidisciplinary approaches has led to the development of “next generation” therapeutics and, with synergistic therapeutic regimes combined with immune checkpoint inhibitors to reactivate the dampened immune response, has provided the much-needed promise for cancer patients. Despite these advances, a large portion of the druggable genome remains understudied, and the role of druggable genome in the immune system needs further attention. Establishment of patient-derived organoid models has fastened the preclinical validation of novel therapeutics for swift clinical translation. We summarized the current advances and challenges and also stress the importance of biobanking and collection of longitudinal data sets with structured clinical information, as well as the critical role these “high content data sets” will play in designing new therapeutic regimes in a tailor-made fashion.
DDC: 610 Medizin
610 Medical sciences
Institution: Johannes Gutenberg-Universität Mainz
Department: FB 04 Medizin
Place: Mainz
ROR: https://ror.org/023b0x485
DOI: http://doi.org/10.25358/openscience-8150
Version: Published version
Publication type: Zeitschriftenaufsatz
License: CC BY
Information on rights of use: https://creativecommons.org/licenses/by/4.0/
Journal: The FEBS journal
288
21
Pages or article number: 6142
6158
Publisher: Wiley-Blackwell
Publisher place: Oxford u.a
Issue date: 2021
ISSN: 1742-4658
Publisher DOI: 10.1111/febs.15788
Appears in collections:JGU-Publikationen

Files in This Item:
  File Description SizeFormat
Thumbnail
druggable_genome_and_precisio-20221021115627142.pdf3.3 MBAdobe PDFView/Open